Release Date: 2024-06-19

Parp Inhibitors Therapy for Metastatic Prostate Cancer

Erdinc Dincer (Author), Cengiz Canakci (Author)

Release Date: 2024-06-19

In this section, the success of targeted therapies that have proven effective in the last 20 years in metastatic prostate cancer is highlighted. Prostate cancer is one of the three most common cancers among men worldwide, and new treatment options are still being investigated. PARP (polyadenosine diphospate ribose polymerase) inhibitors might contribute clinical benefit in [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page111
    Last Page120
    DOIhttps://doi.org/10.69860/nobel.9786053359142.11
    Page Count10
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    In this section, the success of targeted therapies that have proven effective in the last 20 years in metastatic prostate cancer is highlighted. Prostate cancer is one of the three most common cancers among men worldwide, and new treatment options are still being investigated. PARP (polyadenosine diphospate ribose polymerase) inhibitors might contribute clinical benefit in the treatment of homologous recombinant repair (HRR) alterations especially BRCA1/2 . The basis of its working mechanism is "synthetic lethality" and it is an effective treatment that has received FDA approval in the treatment of metastatic prostate cancer, with numerous studies conducted in this field.

    Erdinc Dincer (Author)
    MD, Kartal Dr. Lutfi Kirdar City Hospital
    https://orcid.org/0000-0002-0644-8282
    3The author, Erdinc Dincer is a urologist who is committed to work on the field of urological oncology and endourology. He works at Kartal Dr. Lutfi Kirdar City Hospital, Health Science University. He has contributed to 20 research articles and many oral and poster presentations. He plans a career based on urological oncology, especially prostate and bladder cancer, and continues to improve himself in this field.

    Cengiz Canakci (Author)
    MD, Kartal Dr. Lutfi Kirdar City Hospital
    https://orcid.org/0000-0002-2654-1986
    3Cengiz Çanakcı has been engaged in the practice of urology for over a decade. He has authored numerous research articles, book chapters, and conducted a series of academic studies. He is currently pursuing further academic studies at Health Sciences University Kartal Dr Lütfi Kırdar City Hospital.

    • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

    • Holm M, Doveson S, Lindqvist O, Wennman-Larsen A, Fransson P. Quality of life in men with metastatic prostate cancer in their final years before death - a retrospective analysis of prospective data. BMC Palliat Care. 2018;17:126.

    • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J Clin. 2022;72:7- 33.

    • Elander NO, Hussain SA. PARP Inhibition in Prostate Cancer: A Promising Approach. Oncology (Williston Park). 2016;30:393-4.

    • Longoria O, Beije N, de Bono JS. PARP inhibitors for prostate cancer. Semin Oncol. 2024;51:25-35.

    • Tilki D, van den Bergh RC, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024:S0302-2838(24)02306-6

    • Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F et al. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. Breast. 2022;66:293-304.

    • Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373:1697-708.

    • Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162-74.

    • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382:2091-102.

    • Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094-108.

    • Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023;84(3):321-330.

    • Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR et al;TRITON3 Investigators. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388 :719-32.

    • Smith MR, Scher HI, Sandhu S, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022;23:362-73.

    • Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34 :772-82.

    • de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021;22:1250-1264.

    • Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with firstline metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291-303.

    • Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B et al. Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140-150.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!